NASDAQ: DNLIDenali Therapeutics Inc Stock
$21.93+0.26 (+1.2%)
Updated Jan 17, 2025
DNLI Price
$21.93
Fair Value Price
N/A
Market Cap
$3.16B
52 Week Low
$14.56
52 Week High
$33.33
P/E
-7.92x
P/B
2.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$427.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$363M
Beta
1.35
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DNLI Overview
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DNLI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
C
Sentiment
D
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DNLI
Ranked#372 of 557
Ranked#372 of 557
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.13 | A | |
| $121.18 | A | |
| $5.94 | A |
Be the first to know about important DNLI news, forecast changes, insider trades & much more!
DNLI News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DNLI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DNLI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DNLI is good value based on its book value relative to its share price (2.39x), compared to the US Biotechnology industry average (4.73x)
P/B vs Industry Valuation
DNLI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DNLI due diligence checks available for Premium users.
Valuation
DNLI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.92x
Industry
-135.26x
Market
30.45x
DNLI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.39x
Industry
4.73x
DNLI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DNLI's financial health
Profit margin
Revenue
$0.0
Net Income
-$107.2M
Profit Margin
0%
DNLI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.5B
Liabilities
$135.5M
Debt to equity
0.1
DNLI's short-term assets ($868.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNLI's short-term assets ($868.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNLI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DNLI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$59.1M
Investing
$93.7M
Financing
-$18.6M
DNLI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DNLI vs Biotech Stocks
Denali Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.